healthcare · stock-sale · committee-conflict

Ways and Means Member Unloads UnitedHealth Stock Ahead of 8% Rise

Rep. Kevin Hern's sale of the healthcare giant highlights committee conflicts, though broad portfolio rebalancing suggests routine trading.

2026-10-17 — Kevin Hern · UNH

Key facts

• Rep. Kevin Hern sold between $15,001 and $50,000 of UnitedHealth Group stock on September 23, 2026.
• Hern serves on the House Ways and Means Subcommittee on Health, which oversees Medicare Advantage and health insurance tax policies.
• The stock rose 8.12% after the sale, buoyed by a strong Q3 earnings report and raised guidance on October 13.
• The transaction was part of a larger, same-day batch of eight stock sales, indicating systematic portfolio rebalancing.

Rep. Kevin Hern (R-Okla.) recently disclosed a transaction that highlights the persistent intersection of congressional committee assignments and personal stock portfolios. On September 23, 2026, Hern sold between $15,001 and $50,000 of UnitedHealth Group (UNH) stock.

Hern sits on the powerful House Ways and Means Committee, serving on both its Subcommittee on Health and Subcommittee on Tax. The Health subcommittee has direct legislative oversight over Medicare Advantage and the tax treatment of health insurance—both of which are central drivers of UnitedHealth Group’s multi-billion-dollar business.

Members of Congress are required by the STOCK Act to disclose trades within 45 days, and disclosed amounts are reported in ranges. Hern's disclosure was filed on October 13, 2026, exactly 20 days after the trade.

The timing of the sale is notable. Following the September transaction, UnitedHealth shares climbed 8.12%, rising from a trade-date price of $371.29 to over $401.00. Earlier in the month, UnitedHealth leadership had participated in a Wells Fargo healthcare conference, keeping the market updated on its outlook. On the exact day Hern filed his disclosure, UnitedHealth released its third-quarter earnings report, raising its full-year financial guidance for 2026. Copying the sale would have meant missing out on this post-earnings bump.

However, our analysis scored the transaction a moderate 34 out of 100 for overall signal strength, largely due to signs of systematic portfolio management. The UnitedHealth sale was not an isolated bet; it was executed on the same day Hern sold off positions in seven other unrelated companies, including Home Depot, Devon Energy, Lockheed Martin, and Starbucks. This pattern strongly suggests routine, multi-asset portfolio rebalancing rather than a targeted trade based on non-public information.

Furthermore, legislative catalysts that could affect the insurer had already stalled. The Ways and Means Committee had ordered H.R. 3514—the Improving Seniors’ Timely Access to Care Act, which regulates prior authorizations under Medicare Advantage—to be reported in July 2026, but the bill had not advanced to a floor vote by the time of Hern's trade.

Hern is also a highly active trader, with over 800 transactions since 2018. He has traded UnitedHealth shares 14 times over the last five years, gradually trimming his position through 2025 and 2026. While the trade underscores the inherent conflicts of interest on key committees, it appears to be business as usual for one of Congress’s most active investors.

Sometimes, a conflict of interest is just a routine day at the office.

Sources

1. H.R. 3514: Improving Seniors' Timely Access to Care Act of 2025 — Congress.gov
2. UnitedHealth Group Form 8-K (Reg FD Disclosure) — SEC EDGAR
3. UnitedHealth Group Q3 2026 Form 8-K — SEC EDGAR

All stories · Kevin Hern · UNH